3.11
price up icon1.30%   0.04
after-market After Hours: 3.25 0.14 +4.50%
loading
Prime Medicine Inc stock is traded at $3.11, with a volume of 3.70M. It is up +1.30% in the last 24 hours and up +133.83% over the past month. Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
See More
Previous Close:
$3.07
Open:
$3.23
24h Volume:
3.70M
Relative Volume:
1.87
Market Cap:
$200.88M
Revenue:
-
Net Income/Loss:
$-217.44M
P/E Ratio:
-1.4332
EPS:
-2.17
Net Cash Flow:
$-205.20M
1W Performance:
+17.36%
1M Performance:
+133.83%
6M Performance:
-7.16%
1Y Performance:
-41.76%
1-Day Range:
Value
$3.02
$3.495
1-Week Range:
Value
$2.28
$3.495
52-Week Range:
Value
$1.11
$6.75

Prime Medicine Inc Stock (PRME) Company Profile

Name
Name
Prime Medicine Inc
Name
Phone
617-465-0013
Name
Address
60 FIRST ST., CAMBRIDGE
Name
Employee
214
Name
Twitter
Name
Next Earnings Date
Name
Latest SEC Filings
Name
PRME's Discussions on Twitter

Compare PRME with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
PRME
Prime Medicine Inc
3.11 200.88M 0 -217.44M -205.20M -2.17
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
459.62 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.36 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
331.91 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
543.48 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.49 28.51B 3.81B -644.79M -669.77M -6.24

Prime Medicine Inc Stock (PRME) Upgrades & Downgrades

Date Action Analyst Rating Change
May-27-25 Downgrade Citigroup Buy → Neutral
May-20-25 Downgrade H.C. Wainwright Buy → Neutral
May-20-25 Downgrade JP Morgan Overweight → Neutral
Dec-10-24 Initiated JMP Securities Mkt Outperform
May-20-24 Initiated H.C. Wainwright Buy
May-16-24 Upgrade Citigroup Neutral → Buy
Apr-22-24 Initiated Chardan Capital Markets Buy
Apr-08-24 Initiated TD Cowen Buy
Apr-03-24 Initiated Wedbush Outperform
Jan-16-24 Downgrade Stifel Buy → Hold
Dec-08-23 Initiated Citigroup Neutral
Oct-09-23 Initiated BMO Capital Markets Outperform
Jul-31-23 Initiated Guggenheim Buy
Apr-18-23 Initiated Stifel Buy
Nov-14-22 Initiated Goldman Neutral
Nov-14-22 Initiated JP Morgan Overweight
Nov-14-22 Initiated Jefferies Buy
Nov-14-22 Initiated Morgan Stanley Equal-Weight
View All

Prime Medicine Inc Stock (PRME) Latest News

pulisher
Jun 18, 2025

Prime Medicine’s SWOT analysis: gene editing firm faces cash crunch amid promising tech - Investing.com

Jun 18, 2025
pulisher
Jun 17, 2025

Prime Medicine’s Technological Edge and Strategic Positioning Highlighted as Key Investment Opportunity - TipRanks

Jun 17, 2025
pulisher
Jun 16, 2025

Prime Medicine, Inc. (NYSE:PRME) Major Shareholder Acquires $33,600.00 in Stock - MarketBeat

Jun 16, 2025
pulisher
Jun 14, 2025

Citi Downgrades Prime Medicine (PRME) to Neutral, Cuts PT to $1.50 Due to Market Uncertainty - MSN

Jun 14, 2025
pulisher
Jun 08, 2025

Two Sigma Advisers LP Sells 76,700 Shares of Prime Medicine, Inc. (NYSE:PRME) - Defense World

Jun 08, 2025
pulisher
Jun 07, 2025

Prime Medicine, Inc. (NYSE:PRME) Receives $10.08 Average PT from Brokerages - Defense World

Jun 07, 2025
pulisher
Jun 06, 2025

Prime Medicine stock plummets amid restructuring and leadership changes - MSN

Jun 06, 2025
pulisher
Jun 06, 2025

Bank of America Corp DE Trims Stock Holdings in Prime Medicine, Inc. (NYSE:PRME) - Defense World

Jun 06, 2025
pulisher
Jun 06, 2025

Layoff Tracker: Capsida Downsizes as Part of Shift to Clinical-Stage Company - BioSpace

Jun 06, 2025
pulisher
Jun 05, 2025

Prime Medicine Elects Directors at Annual Meeting - TipRanks

Jun 05, 2025
pulisher
Jun 03, 2025

20,096 Shares in Prime Medicine, Inc. (NYSE:PRME) Bought by BNP Paribas Financial Markets - Defense World

Jun 03, 2025
pulisher
Jun 03, 2025

Jane Street Group LLC Boosts Stock Position in Prime Medicine, Inc. (NYSE:PRME) - Defense World

Jun 03, 2025
pulisher
Jun 02, 2025

Deutsche Bank AG Cuts Position in Prime Medicine, Inc. (NYSE:PRME) - Defense World

Jun 02, 2025
pulisher
May 31, 2025

Altria, Prime Medicine, US Steel, DLocal, Prothena: Trending by Analysts - TipRanks

May 31, 2025
pulisher
May 29, 2025

Prime Medicine Announces Key Presentations at Two Major Healthcare Investor Conferences in June - Stock Titan

May 29, 2025
pulisher
May 29, 2025

Prime Medicine to Participate in Upcoming Investor Conferences - The Manila Times

May 29, 2025
pulisher
May 28, 2025

Prime Medicine’s (PRME) Neutral Rating Reaffirmed at Citigroup - Defense World

May 28, 2025
pulisher
May 27, 2025

Citigroup Downgrades Prime Medicine (PRME) Amid Significant Pric - GuruFocus

May 27, 2025
pulisher
May 27, 2025

Prime Medicine’s SWOT analysis: gene editing firm shifts focus, stock faces challenges By Investing.com - Investing.com South Africa

May 27, 2025
pulisher
May 27, 2025

Citigroup Downgrades Prime Medicine to Neutral From Buy, Adjusts Price Target to $1.50 From $10 - marketscreener.com

May 27, 2025
pulisher
May 27, 2025

Prime Medicine’s SWOT analysis: gene editing firm shifts focus, stock faces challenges - Investing.com Canada

May 27, 2025
pulisher
May 26, 2025

Prime Medicine (PRME) Downgraded by Citi with Reduced Price Targ - GuruFocus

May 26, 2025
pulisher
May 26, 2025

Prime Medicine (PRME) Downgraded by Citi with Reduced Price Target | PRME Stock News - GuruFocus

May 26, 2025
pulisher
May 26, 2025

Prime Medicine downgraded to Neutral from Buy at Citi - TipRanks

May 26, 2025
pulisher
May 26, 2025

Hold Rating for Prime Medicine, Inc. Amid Financial Uncertainties and Strategic Adjustments - TipRanks

May 26, 2025
pulisher
May 25, 2025

Prime Medicine (NYSE:PRME) Earns "Neutral" Rating from JPMorgan Chase & Co. - MarketBeat

May 25, 2025
pulisher
May 24, 2025

Prime Medicine FY2025 EPS Estimate Raised by Chardan Capital - Defense World

May 24, 2025
pulisher
May 23, 2025

Hold Rating on Prime Medicine, Inc. Amid Strategic Shifts and Financial Reevaluation - TipRanks

May 23, 2025
pulisher
May 23, 2025

Critical Analysis: Prime Medicine (NYSE:PRME) and Vigil Neuroscience (NASDAQ:VIGL) - Defense World

May 23, 2025
pulisher
May 22, 2025

Prime Medicine Executives Make Bold Stock Purchases! - TipRanks

May 22, 2025
pulisher
May 22, 2025

Insider Buying: Ann Lee Acquires 100,000 Shares of Prime Medicine Inc (PRME) - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Prime Medicine Executives Make Significant Stock Purchases - TradingView

May 22, 2025
pulisher
May 22, 2025

Prime Medicine CEO Acquires 125,000 Shares - TradingView

May 22, 2025
pulisher
May 22, 2025

Biotech Stock Roundup: BMRN to Acquire INZY, NVAX Gains on Vaccine Approval & More - TradingView

May 22, 2025
pulisher
May 21, 2025

Finance Watch: Prime, Kyverna, Allogene And More Announce Job Cuts - insights.citeline.com

May 21, 2025
pulisher
May 20, 2025

Prime Medicine Announces Layoffs, CEO Transition: Retail Gets More Bullish - MSN

May 20, 2025
pulisher
May 20, 2025

Prime Medicine Cuts Workforce By 25% In Strategic Shift - Finimize

May 20, 2025
pulisher
May 20, 2025

CEO among 25% of staff out the door at cash-strapped Prime - The Pharma Letter

May 20, 2025
pulisher
May 20, 2025

Prime Medicine (PRME) Sees Price Target Adjustment by JMP Securities | PRME Stock News - GuruFocus

May 20, 2025
pulisher
May 20, 2025

This MongoDB Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - Benzinga

May 20, 2025
pulisher
May 20, 2025

Prime Medicine (PRME) Receives Downgrade from JP Morgan | PRME Stock News - GuruFocus

May 20, 2025
pulisher
May 20, 2025

PRME: Prime Medicine Downgraded to Neutral by HC Wainwright & Co - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Prime Medicine downgraded to Neutral from Buy at H.C. Wainwright - TipRanks

May 20, 2025
pulisher
May 20, 2025

Prime Medicine (PRME) Faces Downgrade Amid Strategic Shift | PRM - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Prime Medicine (PRME) Adjusts Strategy Amid Leadership Changes | - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Prime Medicine price target lowered to $6 from $10 at Citizens JMP - TipRanks

May 20, 2025
pulisher
May 20, 2025

Prime Medicine, Inc.: Hold Rating Amid Strategic Restructuring and Long-term Uncertainty - TipRanks

May 20, 2025
pulisher
May 19, 2025

Prime Medicine refocuses on liver disease, leadership changes By Investing.com - Investing.com South Africa

May 19, 2025
pulisher
May 19, 2025

PRME Downgraded by JPMorgan Amid Strategic Shift | PRME Stock News - GuruFocus

May 19, 2025

Prime Medicine Inc Stock (PRME) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Prime Medicine Inc Stock (PRME) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Liu David R.
10% Owner
Jun 23 '25
Buy
2.16
21,000
45,402
20,219,945
Liu David R.
10% Owner
Jun 16 '25
Buy
1.49
21,000
31,196
20,198,945
Liu David R.
10% Owner
Jun 11 '25
Buy
1.60
21,000
33,590
20,177,945
Brudnick Richard
Chief Business Officer
May 20 '25
Buy
1.19
20,000
23,790
20,000
LEE ANN L.
Chief Technical Officer
May 21 '25
Buy
1.13
100,000
113,000
100,000
Reine Allan
Chief Executive Officer
May 21 '25
Buy
1.18
125,000
147,150
125,000
$20.30
price down icon 0.68%
$36.37
price up icon 0.50%
$24.55
price up icon 8.53%
$97.80
price down icon 0.45%
$110.00
price up icon 1.61%
biotechnology ONC
$245.49
price up icon 0.48%
Cap:     |  Volume (24h):